Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma

Shehata, Fatma S.; Abdel-Monem, Nihad; Sakr, M. S.; Kasem, Samar; Balbaa, Mahmoud

doi:10.1007/s12032-013-0673-x

Cited by 16 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its aim was to determine the specific contribution of TGF-β1 over-expression to progression of HCC. These results are in agreement with Shehata et al [13] , who found that TGF-β1 levels were also significantly higher in patients with HCC group compared to chronic hepatitis C patients and control groups.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Association of serum levels of transforming growth factor b1 with disease severity in patients with hepatocellular carcinoma

Kohla¹,

Attia²,

Darwesh³

et al. 2017

View full text Add to dashboard Cite

Aim: Transforming growth factor (TGF) is overexpressed by tumor cells like other proteins and growth factors. TGF-β1 is then activated in the extracellular compartment but is unable to control cell proliferation because of the absence or low level of TGF-β1 receptors on the plasma membrane of malignant hepatocytes. This potential mechanism might interrupt the autocrine regulation loop of TGF-β1 and its blocking effect on cell proliferation. TGF-β1 is a multifunctional cytokine involved in the regulation of growth and differentiation of both normal and transformed cells. This study aimed to evaluate the association of serum levels of TGF-β1 with disease severity. Methods: A total of 180 subjects were classified into 6 groups according to Barcelona clinic liver cancer (BCLC) classification, 30 patients each: early (BCLC 0 and A), intermediate (BCLC B), advanced stage (BCLC C), and terminal stage (BCLC D) of hepatocellular carcinoma as well as 1 group of patients with cirrhosis only and 1 control group. Serum levels of TGF β1 were measured. Results: Serum levels of TGF-β1 were significantly higher in patients with HCC (1,687.47 ± 1,462.81 pg/mL) than cirrhotics (487.98 ± 344.23 pg/mL, P < 0.001) and controls (250.16 ± 284.61 pg/mL, P < 0.001). Conclusion: TGF-β1 may have a role in tumor growth and progression.

show abstract

Section: Discussionsupporting

confidence: 93%

“…These results are in agreement with Shehata et al [13] , who found that there was a significant difference regarding TGF-β1 between early stage (421.9 ± 105.5 pg/mL) and late stage (769.9 ± 115.8 pg/mL) of HCC patients (P = 0.001).…”

Section: In O Ur Stu Dy We De M O Nst R Ate D Si Gni F I C Ant Lysupporting

confidence: 92%

Association of serum levels of transforming growth factor b1 with disease severity in patients with hepatocellular carcinoma

Kohla¹,

Attia²,

Darwesh³

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These results signified the role of EGF in tumor growth and progression. Shehata et al [21] showed higher EGF and transforming growth factor beta 1 levels in patients with HCC compared to the non-HCC counterparts with HCV viral infection and the control subjects. In our study, age and serum EGF levels were the only factors that significantly predicted survival in our HCC patients; higher EGF levels may be associated with tumor aggressiveness and shortened survival.…”

Section: Discussionmentioning

confidence: 98%

“…Cut-off value of 450 had 80% sensitivity while cut-off value of 700 had sensitivity 60.78% and specificity 97% while cut-off value of 900 had sensitivity 39.22% and specificity 98%. Shehata et al [21] showed that significant higher serum levels of EGF in patients with HCC compared to their levels in patients with HCV infection and control subjects with cut-off value of 914 pg/mL, EGF shows 63.3% sensitivity, and 87.5% specificity for HCC patients.…”

Section: Discussionmentioning

confidence: 99%

Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma

Kohla¹,

Al-Haddad²,

Nada³

et al. 2015

Hepatoma Res

View full text Add to dashboard Cite

Aim: Epidermal growth factor (EGF) is a mitogen for hepatocyte grown in vitro, and its expression is up-regulated during liver regeneration. EGF also plays an important role in tumor initiation and progression. The goal of this study is to assess whether EGF is associated with advanced hepatocellular carcinoma (HCC) and also whether it is a predictive factor of shortened survival. Methods: Serum EGF levels were evaluated in a total of 151 subjects: 51 patients with unresectable HCC, (21 of them were eligible for transarterial chemoembolization (TACE) and serum EGF levels were measured before and 1 week after TACE), 40 patients with chronic hepatitis without cirrhosis, 40 patients with cirrhosis, and 20 healthy controls. Patient demographic and laboratory variables were evaluated as predictive factors of survival in a Cox regression multivariate analysis using SPSS software. Results: The mean serum level of EGF in patients with HCC was 784.49 pg/mL, which was significantly higher (P < 0.05) than all other groups. Mean EGF level in cirrhotic patients was 144.69 pg/mL; in those with chronic hepatitis C without cirrhosis, it was 338.64 pg/mL; and in healthy controls, it was 297.15 pg/mL. In group Ia patients who underwent TACE, the mean serum level of EGF was 759.76 ± 287.88 pg/mL before TACE, and 801.14 ± 276.12 pg/mL 1 week after treatment (P = 0.34). On multivariate Cox regression analysis only age (P = 0.03) and higher serum EGF level (P = 0.005), were inversely correlated with overall survival. Conclusion: EGF levels were found to be significantly higher in HCC patients and together with age were the only predictors of poor survival in these patients. There was an increase in EGF levels 1 week after TACE in response to hypoxia; however, this increase was not statistically significant.

show abstract

“…A significant higher serum level of EGF and TGF-β1was recently found in patients with hepatocellular carcinoma compared to their level in patients with chronic hepatitis C infection and control subjects. The levels of phosphorylated EGFR in hepatocellular carcinoma and chronic hepatitis C patients show a highly significant difference between patients [25]. Accordingly, EGF and its phosphorylated form can be used as sensitive biomarkers for the diagnosis and prognosis of these diseases.…”

mentioning

confidence: 99%

Importance of Growth Factors

Balbaa¹

2013

Biochem Physiol

Self Cite

View full text Add to dashboard Cite

Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma

Cited by 16 publications

References 21 publications

Association of serum levels of transforming growth factor b1 with disease severity in patients with hepatocellular carcinoma

Association of serum levels of transforming growth factor b1 with disease severity in patients with hepatocellular carcinoma

Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma

Importance of Growth Factors

Contact Info

Product

Resources

About